

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/74390 A2

- (51) International Patent Classification⁷: **A61K 45/00**
- (21) International Application Number: PCT/IB01/00518
- (22) International Filing Date: 28 March 2001 (28.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0008332.9 4 April 2000 (04.04.2000) GB
- (71) Applicant (*for GB only*): **PFIZER LIMITED** [GB/GB];
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).
- (71) Applicant (*for all designated States except GB, US*):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **FOSTER, Adrian,
Paul** [GB/GB]; Pfizer Global Research and Development,
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).
- (74) Agents: **WOOD, David, J.** et al.; Pfizer Limited, Rams-
gate Road, Sandwich, Kent CT13 9NJ (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/74390 A2

(54) Title: TREATMENT OF RENAL DISORDERS

(57) Abstract: The invention described herein relates to the use of calcium channel blockers such as amlodipine in the treatment of renal disease in normotensive animals. Also described are new unit doses of amlodipine suitable for the treatment of renal disease in normotensive cats.

TREATMENT OF RENAL DISORDERS

This invention relates to the treatment of renal disease in animals, especially chronic renal failure.

5

Renal disease, including renal failure (acute and chronic) is a common clinical problem which tends to increase with the age of animals (including humans). Conditions are described in "The Merck Manual", 16th edition, ch.149, pp.1661,1665 (Merck Research Laboratories (1992), and are
10 commonly, but not always, associated with abnormally high blood pressure (hypertension). Renal disease often results in long suffering periods where the patient endures uncomfortable and painful symptoms, often involving injury to eyes, heart and brain. Dialysis and kidney transplantation can be used as treatments if circumstances allow, but these procedures can have
15 serious complications, including, for transplantation, organ rejection.

In animals the underlying aetiology of the disease can be uncertain, even when histopathological examination has taken place (see e.g. J.Elliott and PJ Barber, J.Small Animal Practice (Feb 1998) vol.39, 78; AR Michell,
20 Vet.Annual (1995) 35:159).

There are many commonly used measurements of renal function such as those mentioned by DR Finco *et al*, in J Vet Intern Med (1999) 13:516-528 - glomerular filtration rate (GFR), plasma creatinine concentration,
25 morphologic examination of kidney tissue, blood urea nitrogen, incidental biological events such as hypertension and proteinurea. Michell (*supra*) defines chronic renal failure as a "failure of clearance". Finco (*supra*) suggests that declining GFR measurements are the most reliable indicator of the disease.

30

Treatment of renal disease associated with hypertension with antihypertensive agents has been propounded, for example with angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, etc. (see e.g. JM Bright, Proc.17th ACVIM, Chicago (1999), pp 134-135). Other treatments
5 are mentioned by Brown, Scott A: Evaluation of chronic renal disease: A staged approach. Compendium on Continuing Education for the Practicing Veterinarian Vol 21: 752-763; 1999.

With regard to chronic renal failure associated with hypertension, treatment with amlodipine has been propounded, e.g. by:

- 10 Henik *et al* in J.Am.Animal Hosp. Assoc., May/June 1997, vol.33);
PS Snyder, in J. Vet.Intern. Med.(1998): 12:157;
KL Cooke *et al*, in J Vet. Intern. Med. (1998); 12:123;
GP Reams *et al*, Am.J.Kidney Diseases (Dec 1987), vol X no.6, 446;
www.ccweb.net/marvistavet/html/body/chronic_renal_failure.html; and
15 CJ Pearce *et al*, New Horizons (1996) vol.4 no.1) 123.

Amlodipine, disclosed in EP 0 089 167, etc., is a dihydropyridine calcium channel blocker which is licensed for use as an antihypertensive and antianginal agent. It is sold as the besylate salt (disclosed in EP 0 244 944,
20 etc.) in 2.5mg, 5mg and 10mg dosages under the trade names Norvasc, Norvas, Istin, Amlor, etc. by Pfizer Inc. and related companies. Both of these publications are herein incorporated by reference.

We have now surprisingly found that calcium channel blockers such as
25 amlodipine (e.g. as the besylate salt) can be used to treat renal disease in animals which are not hypertensive, i.e. animals which are "normotensive". "Normotensive" means having systemic arterial blood pressure values within normal or reference ranges established for the animal species of interest, using acceptable methods for measuring such blood pressure under
30 appropriate circumstances, and below generally accepted "hypertensive" ranges for such animals. Within an animal species, reference range values

may be established for representative subclasses, races, breeds, etc. (e.g. humans, lab. animals, specific subpopulations, etc.).

The prior art does not disclose or suggest that renal disease in
5 normotensive patients, especially normotensive companion animals such as cats, can be treated with a calcium channel blocker such as amlodipine. An aspect of the current invention is the treatment of renal disease in normotensive animals with a calcium channel blocker.

10 Preferably the animal is a mammal.

A preferred mammal is a human.

Another preferred group of mammals are companion animals such as horses, and domestic cats and dogs.

The most preferred companion animal is a domestic cat.

15

Preferably the renal disease is chronic renal failure.

20

Preferably the calcium channel blocker is a dihydropyridine calcium channel blocker such as amlodipine, nifedipine, nitrendipine, nimodipine, nicardipine, felodipine, etc.

The calcium channel blocker can be present as a pharmaceutically acceptable salt or solvate thereof. Pharmaceutically acceptable salts and solvates are non-toxic to the species being treated.

25

Suitable pharmaceutically acceptable salts for dihydropyridine calcium channel blockers include acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, bisulphate, acid citrate, bitartrate, ethansulphonate, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, benzenesulphonate (besylate), p-toluenesulphonate (tosylate), methanesulphonate (mesylate), succinate,

30

salicylate, nitrate, etc.

More preferably the calcium channel blocker is amlodipine and the pharmaceutically acceptable salts thereof, including acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, bisulphate, acid citrate, bitartrate, ethansulphonate, sulphate, phosphate or acid phosphate, acetate, 5 maleate, fumarate, lactate, tartrate, citrate, gluconate, benzenesulphonate (besylate), p-toluenesulphonate (tosylate), methanesulphonate (mesylate), succinate, salicylate, nitrate, etc.

Most preferred is the amlodipine besylate salt.

10

"Pharmaceutically acceptable" and related phrases mentioned herein include the corresponding veterinary equivalents.

"Treatment" refers to prevention, alleviation and/or cure of the condition.

15

Another aspect of the invention is the administration, to a normotensive animal, of an efficacious amount of a calcium channel blocker, such as between 0.01 to 3mg/kg, preferably between 0.1mg/kg and 0.3mg/kg, more preferably between 0.12 and 0.25 mg/kg, amlodipine (preferably 20 administered as the besylate salt) of the animal to treat renal disease such as chronic renal failure.

25

Another aspect of the invention is a unit dosage form of amlodipine which comprises about 0.1-1.5 mg, preferably about 0.2-0.6, or about 0.8 to 1.5 mg, most preferably about 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 or 1.5mg amlodipine per unit, where amlodipine is preferably present as its besylate salt, suitable for, or adapted for, the treatment of normotensive cats with renal disease, such as chronic renal failure. Such unit doses can also be used to treat renal disease in animals with hypertension.

30

Optionally the calcium channel blocker can be administered / formulated with an antihypertensive agent of a different class (i.e. not another calcium channel blocker) such as an agent which reduces the effect of angiotensin and/or endothelin (defined herein as "other active agents").

- 5 Suitable agents include angiotensin converting enzyme (ACE) inhibitors such as those licensed for use in treating hypertension, such as benazepril, benazeprilat, captopril, enalapril, enalaprilat, fosinopril sodium, lisinopril, pentopril, perindopril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, trandolapril, zofenopril calcium, and the like.

- 10 Certain combinations of calcium channel blockers and ACE inhibitors are disclosed in International Patent Application publication no. WO 96/28185, which is herein incorporated by reference.

For such combination therapies, co-administration may take place in a number of different ways, including:

- 15 the active agents may be present in the same dosage form for single administration;
- the active agents may be administered in separate dosage forms, by the same or different administration routes, and at the same, substantially the same or at different times.
- 20 A suitable ACE inhibitor for co-administration in the treatment of renal disease is thought to be benazepril, currently marketed as Fortekor™, which for cats is administered at about 0.5 to about 1mg/kg per day for cats as a 2.5mg or 5mg dose.
- 25 The calcium channel blockers (and/or other active agents) can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice. Suitable pharmaceutical carriers, excipients, diluents,
- 30 etc. can be found in Remington's Pharmaceutical Science, A. Osol, a standard reference text in the field.

For example, the calcium channel blocker (and/or other active agents) can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, syrups, boluses, powders, pastes, drenches ,
5 medicated food or drinking water or other liquid, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.

Such tablets may contain excipients such as microcrystalline cellulose,
10 silicified microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (optionally pre-gelatinised, preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone,
15 hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included. Additionally cyclodextrin solubility modifiers may be included. Additionally antioxidants may be included. Agents to improve palatability,
20 such as flavouring agents (e.g. yeast, yeast extract, pork liver) may also be included. The agents apart from the calcium channel blocker may be present in intimate mixture with the calcium channel blocker, or they may be separated, e.g. in a bilayer, trilayer or other multilayer tablet or coated tablet, or a microparticulate capsule.

25

Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the calcium channel blockers (and/or
30 other active agents) may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents

and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

The calcium channel blockers (and/or other active agents) can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion techniques. For such parenteral administration they are best used in the form of a sterile aqueous solution, or sterile aqueous or oil suspension, which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

The calcium channel blockers (and/or other active agents) can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A [trade mark]) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA [trade mark]), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a

powder mix of the compound and a suitable powder base such as lactose or starch.

Alternatively, the calcium channel blocker (and/or other active agents) can
5 be administered in the form of a suppository or pessary, or may be applied
topically in the form of a gel, a pour-on, spot-on, dip, spray, mousse,
shampoo, collar or powder formulation, ear tag, hydrogel, lotion, solution,
cream, gel, paste, patch, ointment or dusting powder. The calcium channel
blockers (and/or other active agents) may also be dermally or transdermally
10 administered, for example, by the use of a skin patch. They may also be
administered by the pulmonary or rectal routes.

For application topically to the skin, the calcium channel blocker (and/or
other active agents) can be formulated as a suitable ointment containing the
15 active compound suspended or dissolved in, for example, a mixture with one
or more of the following: mineral oil, liquid petrolatum, white petrolatum,
propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying
wax and water. Alternatively, they can be formulated as a suitable lotion or
cream, suspended or dissolved in, for example, a mixture of one or more of
20 the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid
paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-
octyldodecanol, benzyl alcohol and water.

As an alternative for treating animals, the compounds may be administered
25 with the animal feedstuff and for this purpose a concentrated feed additive
or premix may be prepared for mixing with the normal animal feed.

For treatment of companion animals, further delivery devices are envisioned
within the scope of this invention, such as the "chew" or masticable
30 formulations mentioned in GB Patent application nos. 0007112.6 and
0010846.4, and the references therein. These formulations include:

an oral formulation for a medicament comprising:

a solid masticable portion and one or more reservoir portions encompassed by said solid masticable portion;

the solid masticable portion consisting of a fully edible material, having a

5 Young's modulus of 0.01–5MPa, and compressive strength in the range 10–10,000 mJ,

the reservoir portion or portions comprising a releasable dose of the medicament in a fluid (preferably a liquid) form, with a viscosity below 800mPa.s at body temperature (ca. 36-ca.40°C),

10 such that on mastication, the masticable portion is ruptured and the unit dose of the medicament is released in a short space of time from the reservoir portion into the oral cavity.

The calcium channel blockers (and/or other active agents mentioned above)
15 can also be administered together with yet further active agents should the medical need arise.

The physician or veterinarian in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the
20 age, weight and response of the particular patient. The dosages mentioned herein are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention. The skilled person will appreciate that, in the treatment of certain conditions the compounds may be taken as
25 a single or multiple dose as needed or desired.

The route of administration will depend on a number of factors, and in accordance with standard medical and veterinary practice, including the species of animal to be treated, size of the animal, ease of administration,
30 etc.

Based on the results disclosed herein, the envisioned dosage regime for amlodipine in the treatment of renal disease, such as chronic renal failure, in normotensive animals, is 0.125-0.25mg/kg/day.

For the treatment of renal disease in normotensive (and hypertensive) domestic cats the envisioned amlodipine dosage regime is 0.125 - 0.25 mg/kg / day, which translates to 0.4mg/cat/day for cats weighing from 1.6kg up to about 3kg, 0.8mg/cat/day for cats weighing between 3-6.5kg, and 1.2mg/cat/day for cats weighing about 6.5-9.5kg. Cats falling outside these weight ranges will of course be treatable in proportion to their weight. Oral administration is preferred, preferably of a tablet.

Benazepril may be co-administered at 0.5 to 1mg/kg per day, e.g. as a 2.5mg or 5mg dose for domestic cats (as in FortekorTM mentioned above). Other ACE inhibitors and/or endothelin-reducing agents may be co-administered with the calcium channel blocker such as amlodipine according to the medical need, efficacy, etc.

The efficacy of calcium channel blockers such as amlodipine in the treatment of chronic renal failure, in the dosages mentioned and with the populations mentioned can be demonstrated by measurement of renal function (e.g. by GFR measurements or any other measurements known in the art such as renal plasma flow using appropriate markers such as creatinine, inulin, iohexol, radioisotopes and other validated markers of dynamic renal function, urine concentrations of analytes such as protein and/or protein indexed to urine creatinine concentration, etc.).

Measurements can be made before treatment, during treatment and after treatment by methods well-known in the art. For control purposes, a similar population can be treated with a placebo instead of a calcium channel blocker. Efficacy studies should be appropriately controlled for concurrent disease conditions, drug treatments, diet etc. that may confound the interpretation of data used to assess treatment of renal failure, and appropriate statistical analyses applied to variables.

For measurement of blood pressure, e.g. to define the normotensive subpopulation, there are numerous methods mentioned in the art, such as that disclosed by PS Snyder, in J. Vet. Intern. Med. (1998): 12:157. Henik
5 (supra) defines hypertension in cats as a blood pressure of 170mm Hg or more. Some other workers in the field define the level at 175mm Hg or more.

Biological data - Example 1

In this experiment, comparative groups of normotensive nephrectomised
10 cats with chronic renal failure had their GFR measured. One group received placebo and the other received amlodipine besylate once daily at 0.125mg/kg. After 35 days the GFR was measured again. There was no change in the placebo group, but the GFR had increased by an average of ca. 28% for the amlodipine-treated group.

15 Amlodipine besylate at ca. 0.125 mg/kg to ca. 0.25 mg/kg was administered orally by tablet (0.2 mg, 0.4 mg, 0.8 mg and 1.2mg) to normotensive cats (systolic blood pressure of 160mm Hg or less as measured under standard conditions) once daily for a number of weeks, and measurements made at
20 intervals to measure the effect on kidney function in cats presented as veterinary patients with renal problems. In parallel, a number of cats were treated with an oral placebo tablet. Various breeds and crossbreeds of cats of approximately 6 months of age or older were used in the trial. Initial weights of 0.8kg to 9.6 kg were chosen, and the cats were either males or
25 non-pregnant females (entire or neutered). For each animal, the body weight was used to select the appropriate tablet potency of amlodipine (0.125 to 0.25 mg/kg/day) according to the following table:

Body Weight

Kilograms

Pounds

Tablet Potency

(kg)

(lb)

(mg)

0.8 to 1.5	1.8 to 3.5	0.2
1.6 to 3.0	3.6 to 7.0	0.4
3.1 to 6.5	7.1 to 14.0	0.8
6.6 to 9.5	14.1 to 21.0	0.8 + 0.4

Each of the amlodipine tablets used in the study were complemented by placebo tablets with the same excipients and which had the same dimensions and appearance.

Particular amlodipine besylate tablets used had the following compositions:

<u>Names of Ingredients</u>	<u>Composition (mg/unit)</u>
Amlodipine Besylate (1)	0.278
Microcrystalline Cellulose	64.481
Calcium Hydrogen Phosphate, Anhydrous	32.241
Sodium Starch Glycollate	2.000
Magnesium Stearate	1.000
Total	100.000 mg

Presentation	6.0 mm standard round convex white tablet with no engraving
--------------	--

(1) Equivalent to 0.2 mg of amlodipine calculated on a theoretical activity of 72%.

<u>Names of Ingredients</u>	<u>Composition (mg/unit)</u>
Amlodipine Besylate (2)	0.556
Microcrystalline Cellulose	64.296
Calcium Hydrogen Phosphate, Anhydrous	32.148
Sodium Starch Glycollate	2.000
Magnesium Stearate	1.000
Total	100.000 mg

5

Presentation	6.0 mm standard round convex white tablet with no engraving
--------------	--

(2) Equivalent to 0.4 mg of amlodipine calculated on a theoretical activity of 72%.

<u>Names of Ingredients</u>	<u>Composition (mg/unit)</u>

Amlodipine Besylate (3)	1.111
Microcrystalline Cellulose	63.926
Calcium Hydrogen Phosphate, Anhydrous	31.963
Sodium Starch Glycollate	2.000
Magnesium Stearate	1.000
Total	100.000 mg

Presentation	6.0 mm standard round convex white tablet with no engraving
--------------	--

(3) Equivalent to 0.8 mg of amlodipine calculated on a theoretical activity of 72%.

5

The tablets were prepared using standard blending and direct compression techniques. The tablets described herein used the same excipients and manufacturing processes as the commercially available tablets.

10 Biological data - Experiment 2

The data in the Table below were collected from client-owned, pet cats that had been diagnosed with spontaneous chronic renal failure (chronic renal insufficiency). These cats were presented by owners/clients to veterinary practices for evaluation of general health, kidney function, and systolic blood pressure.

15

Chronic renal failure is generally considered an irreversible and progressive disease in cats. Chronic renal failure was diagnosed in each cat in this study. Cats were considered normotensive as defined by systolic arterial blood pressure less than 160 mm Hg prior to the onset of treatment. Cats
 5 were randomly assigned to treatment with either amlodipine besylate tablets at 0.125 to 0.25 mg/kg (as described above) or placebo tablets administered once daily by the oral route.

Renal function was assessed by determining glomerular filtration rate (GFR).
 10 GFR was estimated from plasma clearance of the exogenous marker, iohexol, approximately 7 days prior to the onset of treatment (day -7) and on approximately days 28, 56, 112, and 224 following onset of treatment.

Table - Glomerular filtration rate (mL/min/kg) in cats with chronic renal failure
 15 treated once daily by the oral route with either amlodipine besylate at 0.125 to 0.25 mg/kg or placebo

Day of Study	-7	28	56	112	224
Treatment					
Amlodipine					
Mean GFR	0.76	0.80	0.78	0.85	0.83
Std Deviation	0.29	0.36	0.26	0.31	0.26
Number of Cats	10	9	10	9	10
Placebo					
Mean GFR	0.90	0.89	0.92	0.85	0.75
Std Deviation	0.23	0.22	0.22	0.23	0.30
Number of Cats	13	12	12	13	13

20 In cats receiving amlodipine, GFR increased on average 9% between day -7 and day 224. In contrast, placebo-treated animals experienced a decline in

GFR of 17% between day -7 and day 224. These data demonstrate that amlodipine besylate at 0.125 to 0.25 mg/kg/day orally prevents the decline in function associated with the progression of chronic renal failure in cats.

- 5 Examples of formulations offering 0.4mg and 0.8mg amlodipine respectively, based on a potency of 72.1%, which demonstrated robustness and good stability are described below. These were made by standard direct compression techniques well known in the art.

Components	Quantity/Unit mg/tablet
Amlodipine besylate	0.555 (a)
Microcrystalline cellulose	42.963 (b)
Calcium hydrogen phosphate, anhydrous	21.482
Sodium starch glycollate (type A)	4.000(c)
Dried yeast	30.000 (d)
Magnesium stearate	1.000
	100.000

10

Components	Quantity/Unit mg/tablet
Amlodipine besylate	1.110 (e)
Microcrystalline cellulose	42.593 (b)
Calcium hydrogen phosphate, anhydrous	21.297
Sodium starch glycollate (type A)	4.000(c)
Dried yeast	30.000 (d)
Magnesium stearate	1.000
	100.000

Footnotes:

- 15 (a) Equivalent to 0.4mg/tablet of based on a potency of 72.1%
 (b) As Avicel PH102™
 (c) As Explotab CLV™
 (d) As Debittered brewers yeast 1330
 (e) Equivalent to 0.8mg/tablet of based on a potency of 72.1%

20

CLAIMS

1. The use of a calcium channel blocker optionally in the presence of a antihypertensive agent of a different class, such as an agent that reduces
5 the effect of endothelin and/or angiotensin, in the manufacture of a medicament for the treatment of chronic renal failure in normotensive animals.
2. The use according to claim 1 wherein the calcium channel blocker is a
10 dihydropyridine.
3. The use according to any previous claim wherein the calcium channel blocker is amlodipine.
- 15 4. The use according to any previous claim wherein the calcium channel blocker is amlodipine besylate.
5. A method of treating renal disease in normotensive animals comprising administration of an effective amount of a calcium channel blocker,
20 optionally in the presence of an antihypertensive agent of a different class, such as an agent that reduces the effect of endothelin and/or angiotensin.
6. The method according to claim 5 wherein wherein the calcium channel blocker is a dihydropyridine.
25
7. The method according to any of claims 6 or 7 wherein the calcium channel blocker is amlodipine.
8. The method according to one of claims 5, 6 or 7 wherein the calcium
30 channel blocker is amlodipine besylate.

9. A unit dosage form of amlodipine comprising amlodipine at about 0.1-0.4, or about 0.8 to 1.5 mg, most preferably about 0.1, 0.2, 0.4, 0.8, 1.0, 1.2 or 1.5mg amlodipine per unit, preferably with amlodipine present as the besylate salt,
- 5 optionally in the presence of an antihypertensive agent such as an agent that reduces the effect of endothelin and/or angiotensin, and a pharmaceutical or veterinary carrier, diluent or adjuvant, and which is suitable for the treatment of a companion animal such as a domestic cat.
- 10
10. A unit dosage form according to claim 9 wherein the available amlodipine is present at about 0.4mg or 0.8mg per unit.
11. A pack comprising a formulation of a calcium channel blocker, optionally
- 15 in the presence of a hypertensive agent of a different class, such as an agent that reduces the effect of endothelin and/or angiotensin, and a pharmaceutical or veterinary carrier, diluent or adjuvant, suitable for the treatment of a companion animal such as a domestic cat, and instructions describing the treatment of renal disease in normotensive
- 20 animals.